WhiteSwell
WhiteSwell is a clinical-stage medical device company developing the eLym System, a catheter-based platform that creates a low-pressure zone at the thoracic duct to support lymphatic drainage for acute decompensated heart failure patients unresponsive to diuretics, targeting hospitals and academic medical centers.
- Company typePrivate
- Founded2014
- HeadquartersParkmore, Ireland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What WhiteSwell does
WhiteSwell is a clinical-stage medical device company developing the eLym System, a minimally invasive catheter-based platform designed to treat acute decompensated heart failure (ADHF) by supporting the body's lymphatic system during decongestion. The eLym System is deployed in the left internal jugular and innominate veins near the thoracic duct outflow, where an endovenous micro-axial impeller pump creates a localized low-pressure zone to reduce resistance to lymphatic drainage and enable interstitial fluid removal in conjunction with standard IV diuretic therapy. The company's underlying thesis is that current ADHF therapy with diuretics addresses vascular but not tissue congestion, leaving up to 50% of patients discharged with residual congestion and driving a ~3 million annual hospitalization US market with 25-50% rehospitalization rates within 30 days to 6 months.
The company protects the platform with 40+ US patents granted or pending and has secured FDA Breakthrough Device Designation plus acceptance into the FDA Total Product Lifecycle Advisory Program (TAP). Clinical evidence includes the DELTA-HF feasibility study in 40 patients (announced May 2026), which demonstrated 82.5% freedom from heart failure hospitalization and death at six months, 6.8 kg mean weight loss by discharge, stable renal function, and 100% device deployment success. WhiteSwell is preparing the multi-continent LYMPH-HF randomized pivotal trial.
WhiteSwell is privately held, headquartered in Galway, Ireland, with offices in San Mateo, California, and Shefayim, Israel, employing 11-50 people. It has raised $30 million in a Series B led by RA Capital Management and InCube Ventures in December 2018. As a clinical-stage company, WhiteSwell is pre-revenue and will generate revenue post-approval through direct hospital sales of the eLym System to academic medical centers and cardiovascular hospitals with interventional cardiology capabilities, on a per-procedure hardware sale model.
WhiteSwell firmographics
Firmographics- Name
- WhiteSwell
- Legal name
- WhiteSwell Limited
- Website
- https://whiteswell.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- WhiteSwell is a clinical-stage medical device company developing the eLym System, a catheter-based platform that creates a low-pressure zone at the thoracic duct to support lymphatic drainage for acute decompensated heart failure patients unresponsive to diuretics, targeting hospitals and academic medical centers.
- Ownership category
- akta.pro rank
WhiteSwell industry classification
Industry- Product category
- Cardiovascular Medical Devices
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
Keywords
Where WhiteSwell is headquartered
LocationHeadquarters
- HQ city
- Parkmore
- HQ country
- Ireland
- HQ region
- Europe
Offices3 records
Markets served
WhiteSwell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Medical Device Sales: WhiteSwell is a clinical-stage medtech company developing the eLym System for ADHF treatment. Once regulatory approval is obtained, the company will generate revenue through direct sales of the eLym System to hospitals and healthcare facilities. As a catheter-based therapeutic device used during inpatient hospital stays, revenue will come from device sales to healthcare institutions, likely with recurring procedure-based consumption.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
WhiteSwell product offering
Product offeringCore offering
WhiteSwell develops the eLym™ System, a minimally invasive catheter-based medical device deployed in the left internal jugular and innominate veins that creates a low-pressure zone at the thoracic duct outflow to support lymphatic drainage and enable interstitial decongestion in patients with acute decompensated heart failure (ADHF). The system is used adjunctively with intravenous diuretic therapy during inpatient hospitalization. The company is currently clinical-stage, completing the DELTA-HF feasibility trial and preparing for the LYMPH-HF pivotal trial.
Product overview
WhiteSwell is a clinical-stage medtech company offering the eLym™ System, a single catheter-based medical device for treating acute decompensated heart failure (ADHF). The eLym System is an investigational device that creates a low-pressure zone at the thoracic duct outflow to support the overwhelmed lymphatic system in draining excess interstitial fluid, used concurrently with standard diuretic therapy. The company is currently conducting the DELTA-HF feasibility trial and plans to initiate the LYMPH-HF randomized pivotal trial.
Differentiator
Problem solved
Functional benefit
Brands
- eLym™ System: A catheter-based medical device for treating acute decompensated heart failure by creating a low-pressure zone at the thoracic duct outlet to support lymphatic drainage.
Products and services
- eLym™ System A minimally invasive catheter-based system designed to treat acute decompensated heart failure (ADHF) by creating a low-pressure zone at the thoracic duct outflow to support lymphatic drainage. The system is deployed in the left internal jugular and innominate veins near the thoracic duct connection and works in conjunction with intravenous diuretic therapy to facilitate fluid removal from tissues and organs. It is intended for hospitalized ADHF patients.
Quantifiable outcome
- 82.5% freedom from heart failure hospitalization and death at 6 months (DELTA-HF trial, n=40)
- +6 more outcomes
Companies that use WhiteSwell
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles1 record
WhiteSwell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
WhiteSwell partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered major and core.
- European Society of Cardiology / Heart Failure AssociationmajorWhiteSwell presented primary DELTA-HF clinical trial results at the Heart Failure 2026 Congress organized by the Heart Failure Association (HFA) of the European Society of Cardiology in Barcelona. Results were simultaneously published in the European Journal of Heart Failure.
- U.S. Food and Drug Administration (FDA)coreThe eLym System received FDA Breakthrough Device Designation, which provides priority review and increased engagement with FDA during the approval process. WhiteSwell was also accepted into the FDA's Total Product Lifecycle Advisory Program (TAP), established to expedite patient and physician access to innovative medical devices.
Scale indicators7 records
Recent moves5 records
Expansion highlights4 records
WhiteSwell competitors and assessment
Company assessmentDirect peers
- V-Wave: Clinical-stage cardiovascular device company developing an interatrial shunt for heart failure with preserved ejection fraction. Highly comparable as a heart failure device company at similar clinical/regulatory stage with a structural interventional cardiology approach.
- Corvia Medical: Developer of the Corvia Atrial Shunt, a transcatheter device for heart failure. Direct peer pursuing an interventional approach to address heart failure pathophysiology through a different but adjacent mechanism.
Broad incumbents
- Edwards Lifesciences: Major cardiovascular device incumbent with heart failure and structural heart franchises. Comparable as a potential strategic acquirer and benchmark for cath lab-based device commercialization at scale.
- Abbott: Global medical device leader with significant cardiovascular portfolio including heart failure diagnostics and intervention. Acquired MedNova (where WhiteSwell executives worked) and a logical strategic acquirer profile.
- Medtronic: Largest medical device company with extensive cardiovascular and heart failure portfolio including CRT devices. Represents both competitive overlap (HF treatment) and strategic acquisition interest.
- Boston Scientific: Major cardiovascular device incumbent; WhiteSwell VP Technical Operations previously led Technical Operations at Boston Scientific. Potential strategic acquirer with overlapping structural heart and interventional cardiology capabilities.
- Johnson & Johnson: Acquired Neuravi (WhiteSwell CEO's prior company) and a top-tier cardiovascular strategic. Highly relevant as both benchmark acquirer of similar-stage interventional cardiology companies and as a potential exit path.
Emerging players
- Alleviant Medical: Early-stage company developing a transcatheter interatrial shunt for heart failure. Emerging peer in the structural interventional cardiology space targeting overlapping heart failure populations.
- Procyrion: Developer of the Aortix percutaneous mechanical circulatory support device for heart failure. Emerging peer in catheter-based heart failure therapy, sharing the interventional cardiology delivery model.
Others
- Lungpacer Medical: Catheter-based medical device company addressing underserved clinical needs in respiratory therapy. Comparable as a similarly-staged catheter-based therapy company; WhiteSwell board member Doug Evans is CEO of Lungpacer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
WhiteSwell social profiles
Digital presenceWhiteSwell compliance and trust
Trust signalCompliance1 record
WhiteSwell financial estimates
Financial estimateRevenue estimate
Valuation estimate
WhiteSwell leadership team
Management profileNumber of profiles
Profiles12 records
WhiteSwell funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WhiteSwell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WhiteSwell
What does WhiteSwell do?
WhiteSwell develops the eLym™ System, a minimally invasive catheter-based medical device deployed in the left internal jugular and innominate veins that creates a low-pressure zone at the thoracic duct outflow to support lymphatic drainage and enable interstitial decongestion in patients with acute decompensated heart failure (ADHF). The system is used adjunctively with intravenous diuretic therapy during inpatient hospitalization. The company is currently clinical-stage, completing the DELTA-HF feasibility trial and preparing for the LYMPH-HF pivotal trial.
Is WhiteSwell a public or private company?
WhiteSwell is a private company. It is classified as venture growth investor backed and is currently operating.
When was WhiteSwell founded?
WhiteSwell was founded in 2014. It employs 11 to 50 people.
Where is WhiteSwell based?
WhiteSwell is headquartered in Parkmore, Ireland, in the Europe region.
How does WhiteSwell make money?
One revenue line is on record: medical Device Sales.
Who are WhiteSwell's main competitors?
Direct peers on record are V-Wave and Corvia Medical. Broad incumbents are Edwards Lifesciences, Abbott, Medtronic, Boston Scientific and Johnson & Johnson. Emerging players are Alleviant Medical and Procyrion. Lungpacer Medical is listed as an others.
Does WhiteSwell have an API?
No public API is recorded for WhiteSwell.
What industry is WhiteSwell in?
WhiteSwell's product category is Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT). Its NAICS code is 62151 and its SIC code is 3841.